home / stock / nvsef / nvsef news


NVSEF News and Press, Novartis Ag Basel Akt From 01/18/24

Stock Information

Company Name: Novartis Ag Basel Akt
Stock Symbol: NVSEF
Market: OTC
Website: novartis.com

Menu

NVSEF NVSEF Quote NVSEF Short NVSEF News NVSEF Articles NVSEF Message Board
Get NVSEF Alerts

News, Short Squeeze, Breakout and More Instantly...

NVSEF - Polaris Global Equity Composite Q4 2023 Commentary

2024-01-18 11:00:00 ET Summary Polaris Capital Management, LLC is a leading global value equity manager, serving the investment needs of institutions and individuals since 1995. Polaris has one of the longest global and international equity track records of any firm presently in opera...

NVSEF - Week In Review: China Biopharmas Book $9B In Deals During JP Morgan Conference Week

2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...

NVSEF - Novartis said to have backed away from a deal for Cytokinetics

2024-01-11 12:44:34 ET More on Cytokinetics Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade) Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript ...

NVSEF - Oakmark International Fund: Fourth Calendar Quarter 2023 Commentary

2024-01-10 10:15:00 ET Summary We are value investors. In constructing portfolios for our clients, we seek out companies that we believe are trading in the market at significant discounts to their underlying value. These businesses must offer significant profit potential and be run by...

NVSEF - iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

2024-01-10 08:01:12 ET Summary Data readout from phase 2 GALAXIES Lung-201 study, using belrestotug in combination with dostarlimab to treat patients with 1st-line advanced/metastatic NSCLC, expected 2024. The global non-small cell lung cancer market is expected to reach $36.9 bil...

NVSEF - Novartis AG (NVS) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

2024-01-09 14:50:02 ET Novartis AG (NVS) 2024 J.P. Morgan 42nd Annual Healthcare Conference Call January 8, 2024 09:00 ET Company Participants Vas Narasimhan - Chief Executive Officer Conference Call Participants Richard Vosser - J.P. Morgan Presentatio...

NVSEF - Novartis to buy autoimmune drug developer Calypso Biotech

2024-01-08 11:54:11 ET More on Novartis Novartis: Post Investor Day, Higher Guidance Priced In Novartis AG (NVS) 10th Annual ESG Investor Event Conference (Transcript) Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028 Alphabet unit i...

NVSEF - Alphabet unit inks deals with Eli Lilly and Novartis for AI drug discovery

2024-01-08 11:19:33 ET More on Alphabet Google: Don't Be Too Late To The Party! Google: It Warrants A Large Allocation Google: Time To Load Up (Upgrade) Apple, Alphabet, Broadcom, Nvidia CEOs to meet with EU antitrust chief next week Pinterest and Sna...

NVSEF - Week In Review: 2024 Kicks Off With 3 Deals Worth A Total Of $4B

2024-01-07 04:45:00 ET Summary Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor ADC to R...

NVSEF - Novartis expands production of Pluvicto(TM) with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis

FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...

Previous 10 Next 10